The results of Chen et al. showed that five differently expressed genes, including TNFSF18, can be used as a single biomarker to predict the efficacy of anti-PD-1 in patients with metastatic non-small-cell lung cancer [45]. Here, PDCD1 is linked to non-small cell lung carcinoma.